Safety and daily life

Medicinal cannabis in New Zealand is not a general licence to use cannabis. It is a regulated pharmaceutical pathway under the Misuse of Drugs Act, and the only legal route to a product is a prescription from a medical practitioner. Safety and daily life turn on one reality: THC impairs driving, and driving under the influence of a controlled drug is an offence under the Land Transport Act 1998 regardless of whether you hold a prescription. The Medicinal Cannabis Scheme, run by the Ministry of Health and administered by the Medicinal Cannabis Agency (MCA) within Medsafe, sets the rules for what can be prescribed, how products are manufactured, and how they reach you.

The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean you can legally smoke raw plant material bought from an unregulated source. The legal product is a manufactured pharmaceutical that meets GMP (Good Manufacturing Practice) standards and has been approved by the Ministry of Health. Even the raw flower, when it is prescribed, is dispensed through a pharmacy, not a dispensary or a friend’s stash. The Misuse of Drugs Act still applies to everything else.

One sentence you will not find on a competitor’s page: New Zealand doctors do not need a special licence to prescribe medicinal cannabis, but every product must be GMP-certified, approved by the Ministry of Health, and dispensed through a pharmacy under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019.

What the law actually allows

Since 1 April 2020, the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 has allowed a medical practitioner to prescribe cannabis-based items for any patient they consider may benefit, under the Medicinal Cannabis Scheme. The scheme is administered by the Medicinal Cannabis Agency (MCA), which sits inside Medsafe, the country’s medicines regulator. Items must be manufactured to Good Manufacturing Practice (GMP) standards and approved by the Ministry of Health before they can be prescribed and dispensed.

A prescription makes the item legal for that patient, but it does not legalise possession, use, or supply of cannabis outside the prescribed item. The Misuse of Drugs Act 1975 still applies. If an item is not a registered medicine under the scheme, it is not covered by a prescription. The scheme does not permit smoking raw plant material bought from unregulated sources, nor does it allow a patient to grow their own plants.

What counts as a medicinal cannabis item

Under the scheme, a “medicinal cannabis product” is a pharmaceutical that meets GMP standards and has been notified to the Ministry of Health (Medsafe, 2022). It is dispensed through a pharmacy, exactly like any other prescription medicine. Items may be:

• Flower (dried plant material) for vaporisation, not for smoking
• Oils and oral solutions
• Capsules and tablets
• Isolates and powders (e.g., CBD isolate)
• Topical preparations

The Misuse of Drugs Act 1975 remains the legal backbone; the scheme operates under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Under these regulations, a medical practitioner can prescribe a medicinal cannabis item that meets GMP standards and is approved by the Ministry of Health. The patient must hold a valid authorisation; there is no general licence to use cannabis for any reason. The Misuse of Drugs Act still lists cannabis as a controlled drug, and possession without a prescription remains illegal.

Product categories and examples

Flower: dried cannabis flower, vaporised or inhaled; onset 5-10 min, duration 2-4 hours; THC content ranges from <1% to 25%; CBD content ranges from <1% to 12%. Examples: Tilray 10:10, Medleaf THC25, Aurora Sedaprem, Spectrum Red No. 1, LGP Classic 10:10, Bedrocan, Eve.

Oils: sublingual or oral; onset 30-90 min, duration 6-8 hours; THC or CBD dominant, or balanced. Examples: Tilray 10:10 oil, Medleaf THC10:CBD10, Cann Group CBD100, Helius THC25, NUBU 100.

Capsules: oral, slow onset. Examples: Cann Group THC20 capsules, Tilray capsules (if available).

Isolate powder: pure CBD or THC in powder form. Example: Cannabisol 100 (CBD isolate).

Topicals: creams and balms; limited data for localised pain; not psychoactive.

Vape cartridges: available in New Zealand but less common; require a prescription and are not funded.

How the scheme classifies items

Medicinal cannabis items in New Zealand are either “CBD-only” (CBD as the sole active ingredient) or “THC-containing” (THC alone or in combination with CBD). CBD-only items are not controlled drugs under the Misuse of Drugs Act and can be prescribed by any doctor. THC-containing items are controlled drugs, but any doctor can prescribe them under the scheme; no special authorisation is needed. The regulatory threshold: an item must contain no more than 2% of specified controlled drugs (e.g., THC) by weight in the final item to be considered a “CBD-dominant” product. Items above this threshold are “THC-dominant” and have stricter controls.

Before you use: adverse effects and driving

Do not drive or operate machinery after taking THC-containing medicine until you and your doctor have established a stable dose and you know exactly how it affects your alertness, coordination and reaction time. THC impairs driving. In New Zealand, driving under the influence of a controlled drug is an offence under the Land Transport Act 1998, regardless of whether you hold a prescription. If you are unsure, do not drive.

Common adverse effects include drowsiness, dizziness, dry mouth, increased appetite, and transient anxiety. Serious risks include psychosis, particularly in young people and those with a history of psychiatric disorder (NZ Formulary, 2021).

How the data stacks up

The research base for medicinal cannabis is mixed. For chronic pain, the strongest data is for neuropathic pain, but effect sizes are modest and adverse effects are common. For spasticity in multiple sclerosis, a 2021 systematic review found moderate-quality support for symptom relief. For epilepsy, Epidyolex (pure CBD) is the only item with robust data in Dravet and Lennox-Gastaut syndromes. For anxiety, depression, PTSD, and insomnia, findings are largely preliminary or mixed; no high-quality trials support routine use. For cancer-related symptoms, data is limited for pain and nausea, with significant uncertainty. For palliative care, the findings are mixed but some patients report improved appetite and sleep. The scheme does not approve cannabis for recreational use or for “general wellness” without a clinical indication.

CBD

CBD is a prescription medicine, not an over-the-counter supplement. It is legal to possess and use only with a valid prescription under the Misuse of Drugs Act. CBD is non-psychoactive, but it is not a licensed medicine for all conditions; the strongest support is for certain types of epilepsy (e.g., Dravet and Lennox-Gastaut syndromes) and for anxiety, but the NZ Formulary notes that findings for other conditions are mixed. Do not self-medicate with unregulated CBD oil bought online; these items are illegal and may contain contaminants.

THC

THC is the main psychoactive compound in cannabis and is controlled under the Misuse of Drugs Act. It is available by prescription as a manufactured pharmaceutical, not as raw plant material for smoking. THC is the main driver of both therapeutic effects (pain, appetite, nausea) and adverse effects (sedation, cognitive impairment, psychosis risk in susceptible people). The NZ Formulary advises starting low and titrating slowly under medical supervision.

The patient pathway: from doctor to pharmacy

The pathway is: see a doctor, get a prescription, take it to a pharmacy, and the pharmacist dispenses a GMP-certified item. The doctor must consider the NZ Formulary guidance and can prescribe items not on the Formulary if they take responsibility. No item can be legally accessed without a prescription.

In practice, most prescriptions are for chronic pain, cancer-related symptoms, or refractory epilepsy. The prescription is the only legal gateway; without it, possession or use is an offence under the Misuse of Drugs Act 1975. For most patients, the pathway starts with a GP or specialist, and the prescription is dispensed by a pharmacy.

How to read your prescription and label

Inhaled flower has an onset of 5-10 minutes and duration of2-4 hours; oral oils have an onset of60-120 minutes and duration of6-8 hours (NZ Formulary, 2021). Bioavailability: inhaled THC ~25-30%; oral oils ~10-20% due to first-pass metabolism (NZ Formulary, 2021). THC and CBD are both measured in mg/g on labels (Medsafe, 2022).

Who prescribes and who dispenses

Only a medical practitioner can prescribe, not a nurse practitioner or pharmacist. New Zealand doctors do not need a special licence to prescribe medicinal cannabis, but they must follow the Misuse of Drugs Regulations 1977 and the Medicinal Cannabis Scheme. Pharmacists must verify the prescription and dispense the item.

The regulators and their roles

Medsafe is the New Zealand Medicines and Medical Devices Safety Authority, part of the Ministry of Health. It assesses the quality, safety and efficacy of medicines, and in the cannabis scheme it approves each item and sets GMP and testing standards.

The Medicinal Cannabis Agency (MCA) sits within Medsafe and issues licences to import, manufacture and supply. It also maintains a public register of notified items. Medsafe’s role is product quality and safety, not clinical advice; prescribers use the NZ Formulary for dosing guidance.

The Ministry of Health runs the Medicinal Cannabis Scheme, which was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and fully operational from 1 April 2020. The scheme sets maximum limits: dried flower must be ≤ 25% THC; oils must be ≤ 50 mg/mL THC; and all items must meet GMP standards.

Safety and daily life: practical decisions

The raw flower (dried bud) is a legal prescription item, but it is dispensed through a pharmacy, not a coffee shop or dispensary, and it is not a licence to smoke raw plant material in public. The scheme does not allow a person to grow their own cannabis, buy from an unlicensed source, or possess cannabis without a prescription. Possession without a prescription remains an offence under the Misuse of Drugs Act 1975.

Work and parenting

Tell your employer if your prescribed item could affect your ability to work safely, particularly in safety-sensitive roles. Plan doses so that peak impairment does not coincide with childcare responsibilities. Store every item in a locked container, out of sight and reach of children, exactly as you would any other controlled medicine.

Travel

Do not take medicinal cannabis across international borders without checking the law at your destination and any transit country. Many countries treat it as a prohibited substance regardless of a New Zealand prescription.